News

Emgality is a monthly subcutaneous injection. Here’s how it prevents migraine and treats cluster headaches.
Organon and Eli Lilly and Company have broadened their commercial agreement under which the former will be the sole distributor and promoter of the migraine medication Emgality (galcanezumab) in ...
Eli Lilly and Organon expand commercialization deal for migraine medicine Emgality in 11 new markets, with Organon as sole distributor.
Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets The agreement builds on Organon’s global product portfolio for conditions that impact women disproportionately.
Jersey City-based Organon is expanding its distribution and promotion agreement with Eli Lilly and Co. for migraine medicine Emgality.
If Eli Lilly and Co. had been hoping its migraine drug, Emgality (galcanezumab), would emerge with unequivocal superiority against Pfizer Inc.’s Nurtec ODT (rimegepant orally disintegrating tablet), ...
Lilly Forward-Looking Statement This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Emgality ...
INDIANAPOLIS, June 16, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced results of the CHALLENGE-MIG clinical trial of Emgality ® (galcanezumab-gnlm) and Nurtec ® ODT (rimegepant ...
Eli Lilly And Co (NYSE: LLY) announced the results of the CHALLENGE-MIG clinical trial of Emgality (galcanezumab-gnlm) and Nurtec ODT (rimegepant orally disintegrating tablet).
Lilly's Emgality was approved in 2018 in the U.S. for preventive treatment of migraine in adults, and Pfizer's Nurtec ODT in 2020 for treatment of acute migraine and its use was expanded to cover ...
A federal jury in Boston awarded Teva Pharmaceuticals International GmbH $176.5 million in damages in a patient infringement suit against Eli Lilly and Co. for its migraine medication, Emgality.
A federal jury has asked Eli Lilly And Company (NYSE: LLY) to pay Teva Pharmaceuticals International GmbH $176.5 million after a trial to determine whether its migraine drug Emgality infringed ...